Perspective Therapeutics (CATX) Research & Development (2010 - 2026)

Perspective Therapeutics has disclosed Research & Development across 17 years of filings, most recently posting $21.5 million for Q2 2026.

• In Q2 2026, Research & Development rose 29.63% year-over-year to $21.5 million; the TTM figure through Jun 2026 stood at $73.9 million (up 32.23% YoY), while the FY2025 annual figure was $84.2 million, up 102.26% from the prior year.
• Research & Development came in at $21.5 million for Q2 2026 at Perspective Therapeutics, up from $21.4 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $21.5 million in Q2 2026 to a low of $468000.0 in Q4 2022.
• Average Research & Development over 5 years is $8.8 million, with a median of $7.3 million recorded in 2023.
• Year-over-year, Research & Development tumbled 33.33% in 2022 and surged 1412.82% in 2023.
• Over 5 years, Research & Development stood at $468000.0 in 2022, then surged by 1412.82% to $7.1 million in 2023, then soared by 81.96% to $12.9 million in 2024, then climbed by 29.01% to $16.6 million in 2025, then advanced by 29.63% to $21.5 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $21.5 million in Q2 2026, $21.4 million in Q1 2026, and $16.6 million in Q2 2025.